Podcast Summary: "LDL Isn’t the Problem? The Real Drivers of Heart Disease"

Podcast: The Metabolic Classroom with Dr. Ben Bikman
Host: Insulin IQ
Episode Date: February 16, 2026

Episode Overview

In this thought-provoking mini-lecture, Dr. Ben Bikman challenges the conventional wisdom that low-density lipoprotein (LDL) cholesterol is the primary cause of heart disease. Instead, he explores the evidence showing that metabolic health—specifically, insulin resistance and markers like the triglyceride to HDL cholesterol ratio—are much stronger predictors of cardiovascular risk than LDL alone. Dr. Bikman cites large studies and guides listeners toward a metabolism-centric approach to prevention, highlighting actionable markers that everyone can check with a standard blood test.

Key Discussion Points & Insights

1. Challenging the LDL-Centric Narrative

Common Assumptions: The long-standing medical narrative equates high cholesterol, especially LDL, with heart disease (“Cholesterol clogs your arteries like grease in a pipe.” — Ben Bikman [02:05]).
Contradictory Evidence:
- Nearly half of people who have heart attacks have normal LDL cholesterol levels.
- In a study of over 136,000 with coronary artery disease, almost half had LDL below 100 mg/dL; 18% had below 70 mg/dL.
- Only ~21% were on cholesterol-lowering medication prior to hospitalization, suggesting their “normal” LDL wasn’t due to over-treatment ([03:13]).
"These were people developing heart disease despite having LDL levels that even current guidelines would consider perfectly acceptable, even ideal in some cases."
— Ben Bikman [04:15]

2. Comparing Predictive Markers: LDL vs. Metabolic Health

LDL’s Weak Predictive Value:
- LDL’s association with heart disease is “very weak very quickly" compared to metabolic parameters ([05:12]).
- Studies show only a modest increased risk (e.g., 1.4x for LDL, 1.9x for apolipoprotein B).
Insulin Resistance as a Superior Predictor:
- The lipoprotein insulin resistance score had a >6-fold increased risk for premature heart disease (<55 years) versus ~1.4–1.9-fold for lipid markers ([06:10]).
- Type 2 diabetes confers a >10-fold increased risk of heart disease ([07:02]).
- Metabolic syndrome increases risk about 6-fold for premature coronary disease ([07:35]).
"The lipoprotein insulin resistance score wasn't just slightly better. It was in a completely different league." — Ben Bikman [06:53]

3. The Power of the Triglyceride to HDL Ratio

Easy Calculation, High Predictive Value:
- "The humble triglyceride to HDL ratio still outperforms even the best of the LDL related markers" ([08:23]).
- A ratio above 2 (mg/dL units) is concerning; 3 or higher is a red flag.
- The ratio signals insulin resistance: high triglycerides (+) low HDL (−).
Clinical Implications:
- In the Copenhagen Male Study, men with identical LDL but high TG/HDL ratio had >3x the risk of heart disease than those with a favorable ratio ([11:15]).
- "You could have two patients both with LDL of 165 mg/dL... but if one has high triglycerides and low HDL while the other has low triglycerides and high HDL, their actual risk... differs by more than threefold."
  — Ben Bikman [12:35]
Mechanism: Insulin resistance leads to higher triglycerides and lowers HDL, but may not elevate LDL ([09:57]).

4. Sex Differences & Nuances

Men vs. Women:
- "Insulin resistance may actually predict CVD more strongly in men than in women in certain populations." ([18:00])
- Diabetes increases relative cardiovascular risk more in women ("about 25 to 50% greater excess risk" in women than men) ([19:05]).
- TG/HDL cutoff: 3.5 in men, 2.5 in women is high risk ([19:55]).

5. Questioning Statin-Based Prevention

Primary Prevention Limitations:
- In large statin trials, 60–100 people must be treated for 5 years to prevent one event ([20:35]).
- Many who have heart attacks already had LDL at target despite medication.
- Statins don't improve metabolic health—and can increase diabetes risk by 50%, particularly in women ([21:35]).
“The issue isn’t necessarily that these medications aren’t lowering LDL... But the issue is that LDL reduction doesn’t really appear to do much.” — Ben Bikman [20:53]

6. Takeaway Principles for Cardiovascular Prevention

Shift Focus:
- “We need to shift our focus from being LDL-centric to being metabolism-centric.” ([22:53])
- Insulin resistance indicators (high fasting insulin, TG/HDL, type 2 diabetes) are more worrisome than modest LDL elevations.
- Diet and lifestyle—especially reducing refined carbohydrates and increasing physical activity—are the most potent interventions.
- Lipid markers should be assessed in the context of metabolic health.
Concluding Thought:
- "The narrative we’ve been told about cholesterol and heart disease is not necessarily wrong, but it is not right, and it is very incomplete." ([25:40])
- “The markers that matter most aren’t necessarily the ones we can most easily treat with a pill. That is such a profound idea that I hope resonates with you.” ([26:05])

Notable Quotes & Memorable Moments

On Conventional Risk Markers:
- "LDL cholesterol may matter, but it’s not the primary driver of cardiovascular disease that we’ve been led to believe." ([25:44])
On Accessibility of Testing:
- "You don’t need specialized testing. Just take your triglyceride level and divide it by your HDL cholesterol level. A ratio above 2... starts to be a warning sign." ([10:31])
On Clinical Practice:
- “One of the reasons we focus on LDL so much has less to do with its ability to predict... and more to do with the fact that it is a druggable target. We have drugs that can lower LDL very well... part of modern medicine... is driven by profit.” ([26:14])
On Lifestyle:
- "The food we eat is either the culprit or the cure." ([26:41])

Timestamps for Key Segments

| Segment | Description | Timestamp (MM:SS) | |---------|-------------|------------------| | Introduction & Challenge to LDL | Dr. Bikman introduces the main argument about conventional cholesterol wisdom | [01:53] – [05:12] | | LDL vs. Metabolic Predictors | Discussion of large population studies, LDL’s weak predictive value | [05:13] – [07:55] | | The Triglyceride to HDL Ratio | Explanation, studies, real-world clinical implications | [08:00] – [13:30] | | Sex Differences in Prediction | Differences between men & women regarding insulin resistance and risk | [17:20] – [19:55] | | Statins in Primary Prevention | Statin efficacy, limitations, unintended effects | [20:35] – [21:45] | | Practical Prevention—What Should Change?| Synthesis and summary recommendations | [22:53] – [26:41] |

Summary Table: Major Risk Predictors

| Marker / Condition | Risk Increase for Premature CVD | |--------------------------------------|---------------------------------| | Lipoprotein Insulin Resistance Score | >6-fold | | Type 2 Diabetes | >10-fold | | Metabolic Syndrome | ~6-fold | | LDL Cholesterol | 1.4-fold | | Apolipoprotein B | 1.9-fold | | Triglyceride to HDL Ratio | >2-fold; up to 3-fold in some studies |

Final Message

Dr. Bikman urges clinicians and patients alike to reevaluate what truly drives cardiovascular risk. While LDL is a factor, markers of insulin resistance—like the triglyceride to HDL ratio—are more powerful and accessible predictors that we should focus on for meaningful prevention.

"Remember, more knowledge, better health."
— Ben Bikman [26:48]

Transcript

Capital One Bank Announcer (0:00)

With no fees or minimums on checking accounts, it's no wonder the Capital One bank guy is so passionate about banking with Capital One. If he were here, he wouldn't just tell you about no fees or minimums. He'd also talk about how most Capital One cafes are open seven days a week to assist with your banking needs. Yep, even on weekends it's pretty much all he talks about in a good way. What's in your wallet? Term supply see capitalone.com bank capital1na member FDIC close your eyes. Listen to Monday.com feel the sensation of an AI work platform so flexible and intuitive it feels like it was built just for you. Now open your eyes, go to Monday.comstart for free and finally breathe.

Skyrizi Patient Testimonial (0:47)

My perfect day has sand, salt water and friends, but my moderate to severe plaque psoriasis can take me out of the moment. Now I'm all in with clearer skin thanks to skyrizi risen Kizumab RZA, a prescription only 150 milligram injection for a adults who are candidates for systemic or phototherapy with Skyrizi. Most people saw 90% clearer skin and many were even 100% plaque free at four months. Skyrizi is just four doses a year. After two starter doses.

Medical Expert / Podcast Host (Ben Bickman) (1:14)

Don't use if allergic to Skyrizi. Serious allergic reactions, increased infections or lower ability to fight them may occur before treatment. Get checked for infections and tuberculosis. Tell your doctor about any flu like symptoms or vaccines.

Skyrizi Patient Testimonial (1:26)

Thanks to Skyrizi, there's nothing on my skin and that means everything is everything. Ask your doctor about Skyrizi, the number one dermatologist prescribed biologic in psoriasis. Visit skyrizi.com or call 1-866-Skyrizi to learn more.

Medical Expert / Podcast Host (Ben Bickman) (1:53)

Welcome to the Metabolic Classroom Podcast. I'm Ben Bickman. Thanks for letting me be your guest professor for the next few minutes. Don't worry about any pop quizzes. I'm here to simply make the science of metabolism clear, practical and engaging. Welcome back to the Metabolic Classroom. I'm Ben Bickman, metabolic scientist and professor of cell biology. Today's mini lecture aims to teach you about the clinical markers that seem to best predict heart disease risk and to challenge some assumptions you might have about cholesterol when it comes to heart disease prevention. We've been told a story. It goes something like Cholesterol clogs your arteries like grease in a pipe. So if we just lower LDL cholesterol enough, we can prevent heart attacks. The narrative has driven decades of medical practice and billions of dollars in statin prescriptions, drugs designed to lower LDL cholesterol. But what if I told you that nearly half of people who have heart attacks have normal LDL cholesterol? What if the markers we obsess over, like LDL or apolipoprotein B or lipoprotein A aren't actually the strongest predictors of who will develop heart disease? Today? I want to show you that the evidence actually says that metabolic health may matter more than these lipid markers. And in fact, metabolic health may matter most. Let's start with a striking observation from a massive study of over 136,000 people hospitalized with coronary artery disease. When researchers looked at their LDL cholesterol levels at admission, they found something remarkable. Almost half had LDL levels below 100 milligrams per deciliter. Nearly 18% had LDL below 70 milligrams per deciliter, well within what guidelines would consider optimal these days, even among patients with no prior history of heart disease, diabetes or vascular disease. People having their first cardiac event, in other words, over 40% had LDL below 100 milligrams per deciliter and nearly 72 were below 130 milligrams per deciliter. Very modest, normal numbers. Think about that. These weren't people with sky high cholesterol finally catching up with them. These were people developing heart disease despite having LDL levels that even current guidelines would consider perfectly acceptable, even ideal in some cases. And here's what else they found. Only about 21% of these patients were taking cholesterol lowering medications before their hospitalization. So this wasn't about over treatment driving LDL too low. These were naturally occurring cholesterol levels that clearly weren't protecting against heart disease. Now, I'm not saying LDL doesn't matter at all. It might. It may have some association with cardiovascular risk. It may have some causal role here. But when you look at the strength of the association with LDL and heart disease compared to other markers, particularly those in the metabolic realm, LDL starts to look very weak very quickly. So if LDL isn't the smoking gun we've been told it is, what is? The evidence increasingly points to insulin resistance and its related metabolic disturbances as far more powerful predictors of cardiovascular disease, especially premature heart disease. A comprehensive study following nearly 28,000 participants for over 21 years examined more than 50 different biomarkers for their ability to predict heart disease at different ages. When they looked at individuals who developed heart disease before age 55, what we would call premature coronary disease. They found something fascinating of all the biomarkers measured, the lipoprotein insulin resistance score had the highest predictive value value for individuals under 55. This marker was associated with a greater than six fold increased risk of developing heart disease. After adjusting for any other risk factor. Compare that to LDL cholesterol in the same population, only a 1.4 fold increased risk. Non LDL cholesterol 1.7 fold. Even apolipoprotein B, which many lipidologists consider superior to LDL, anything including LDL showed only a 1.9 fold increased risk. The lipoprotein insulin resistance score wasn't just slightly better, it was in a completely different league. It was multiples better at predicting heart disease risk retrospectively so looking back in time than even the so called best lipid marker, the apolipoprotein bio. And here's the critical part. The association with insulin resistance was strongest for premature heart disease and gradually weakened with age. This pattern suggests that metabolic dysfunction is particularly important in driving cardiovascular disease in relatively younger people. Type 2 diabetes showed a similar pattern. In individuals under 55 having diabetes was associated with more than a 10 fold increased risk of heart disease. Remember, apolipoprotein B, the so called best marker was only 1.9. Diabetes is a tenfold increased risk. This association remained strong across all age groups, but again it was strongest in the younger people, those at middle aged up to about 55. Metabolic syndrome, that cluster of insulin resistance triglycerides are high, low hdl, elevated blood pressure and abdominal obesity was about a six fold increased risk for premature heart disease. So still far exceeding any of the lipid markers like apolipoprotein B or ldl. Now there's a simple marker that you can calculate and I've in fact mentioned it here, it's for those who are paying attention and you can figure this out from any standard lipid panel that you're going to get. So anytime you've gone in and gotten your blood drawn, you're going to have these markers and they almost all the time. This these markers when used together will outperform LDL cholesterol. So it will help you get perhaps the best way you can with the blood markers you have an assessment of your heart disease risk and that is the triglyceride to HDL ratio. In one of the in one particular study, in fact one of the ones I mentioned earlier, the triglyceride to HDL ratio showed more than a twofold increased risk for heart disease in younger individuals. So not only Was that substantially stronger than LDL alone, But it was even stronger than the much obsessed over and much adored apolipoprotein B. So again, the humble triglyceride to HDL ratio still outperforms even the best of the LDL related markers. But let me tell you about another study that really drives this point home. Researchers wanted to find a simple way to identify insulin resistant individuals at increased cardiovascular risk. They measured insulin Resistance directly in 449 apparently healthy people and then looked at which routine lipid measures best predicted who was insulin resistant. In other words, are there some lipid markers that can be used to assess insulin resistance in the event that you aren't able to get your insulin measured? The winner, the triglyceride to HDL cholesterol ratio. It was the best predictor of insulin resistance and of small, dense LDL particles. So within the family of LDL is a wide or broad spectrum of how big and fluffy or small and dense they are. And the small, dense LDL particles. Particles are thought to be or are often more implicated in driving heart disease risk. In fact, the triglyceride to HDL ratio identified insulin resistant patients with a sensitivity and specificity comparable to the criteria for diagnosing metabolic syndrome. A ratio of 3.5 or higher was a good cutoff in this study for identifying those at high risk. So when you started to get around three red flag. Now, why does the ratio matter so much? It's essentially a crude but effective marker of insulin resistance. A poor man's method, if you will. When you're insulin resistant, your liver over produces triglyceride rich particles like those in VLDL and ldl, but not the LDL number. Here it's the amount of triglycerides they're carrying. And your HDL cholesterol tends to be low. The insulin resistance that is, on one hand, overproducing triglycerides is actually accelerating the uptake of HDL back into the liver, thereby reducing the amount of HDL in circulation. So this ratio can capture that metabolic dysfunction in a way that LDL alone simply cannot. The beauty of the marker is its simplicity. You don't need specialized testing. Just take your triglyceride level and divide it by your HDL cholesterol level. A ratio above 2, if you're using. If these units coming in the triglycerides and the HDL cholesterol are in milligrams per deciliter. If it's above 2, that starts to be a warning sign. You want it to be less than 2. In other words, when it gets to 3, as I noted earlier, that is red alert. But perhaps the most compelling demonstration of the triglyceride to HDL ratio's predictive power comes from the Copenhagen male study. In a cohort of nearly 3,000 men followed for eight years, researchers tested a specific hypothesis. Would men with conventional risk factors still have low heart disease risk if they had a favorable triglyceride to HDL pattern? And conversely, would men without those conventional risk factors, namely LDL cholesterol, still be at high risk if their triglyceride to HDL pattern or ratio was unfavorable? To answer this, they divided participants into three groups based on their metabolic profile. Those with low triglyceride and high hdl, the favorable pattern, those with high triglycerides and low hdl, the unfavorable pattern, and an intermediate group. So, in other words, they're splitting them up based on their triglyceride to HDL ratio. Then they examined heart disease incidence across different LDL levels. So can you see or understand the different things here? So they're looking at who's having heart attacks and who's not. Then they're looking at their triglyceride to HDL ratio, and they're comparing that to their LDL cholesterol levels. The results are remarkable. And in fact, those of you who are insiders, I encourage you to look up this study. It is open access, and you can get access to the citations to read it there. The figure is very, very telling. Among men with LDL levels, LDL cholesterol levels at or below 170 milligrams per deciliter. What most clinicians would consider kind of an acceptable cutoff. The incidence of ischemic heart disease varied dramatically based on their triglyceride to HDL ratio. Men with the unfavorable ratio. So high triglyceride, low HDL, had about 14% incidence of heart disease over those eight years. But men with the same LDL levels who had the low triglyceride HDL ratio, they only had about a 4% incidence. So it's a fraction. It's about less than 30% of the same risk. In the men who had high triglyceride HDL ratio. Remember, even though their LDL levels were the same. So that's more than a threefold difference in heart disease risk among people with identical LDL cholesterol levels. The only thing different, their triglyceride to HDL ratio. But this wasn't just about low LDL being protective even among men with high LDL cholesterol to those above 170 milligrams per deciliter. Those with favorable triglyceride to HDL ratios so low only had 5% heart disease incidence. Meanwhile, men with similarly elevated LDL but unfavorable triglyceride to HDL ratio about 12%. So it's actually lower than those who had low LDL, but a bad triglyceride to HDL ratio, ironically. Now think about the clinical implications here. You could have two patients both with LDL cholesterol of 165 milligrams per deciliter, a perfectly acceptable level by conventional standards. But if one has high triglycerides and low HDL while the other has low triglycerides and high hdl, their actual risk of developing heart disease differs by more than threefold. The LDL number tells you almost nothing about which patient is actually at risk. This finding underscores a critical reality. Metabolic health reflected in triglyceride HDL ratio in this case is a far more powerful predictor than LDL cholesterol is alone. It's the underlying metabolic dysfunction, not just the cholesterol number, that drives the cardiovascular disease risk. Multiple studies across different populations have confirmed the predictive power of this ratio in patients with stable angina, for example. So ongoing chest pain, the highest quartile of triglyceride to HDL ratio, was associated with a nearly three fold increased risk of death or heart attack, independent of any other risk factors. Notably, there were no differences in total cholesterol or LDL cholesterol across the triglyceride to HDL ratio quartiles in that study. Even still, the cardiovascular risk was dramatically different. And again, that risk coincided with changes in the triglyceride to HDL ratio, not the other LDL related markers.